In an article on a federal probe into Johnson & Johnson鈥檚 marketing of an antipsychotic drug, the Wall Street Journal quoted Dean聽 on the risks the company might face in going to trial.
In filings with the Securities and Exchange Commission, J&J acknowledged a federal investigation into the firm鈥檚 marketing of Risperdal for unapproved uses, the article said, citing sources that set the potential settlement at $1 billion.
Should the New Jersey-based company not agree to the terms of the settlement sought by the federal government, the resulting trial, if unsuccessful for J&J, could result in more costly civil and criminal legal actions brought by patients and states, Dennis said.
The article appeared in the May 13, 2011 edition of the newspaper.